Monday, August 10, 1998
OXFORD - Troubled British Biotech plc is piecing together its
rehabilitation package. Last Tuesday, the company announced that it had recruited Chris
Hampson, a former top executive at the British chemicals giant ICI, to replace John
Raisman as its non-executive chairman on Oct. 1.
There had been a great deal of speculation that Raisman would fall
victim to the Millargate affair, which has already claimed BBG's CEO Keith McCullagh,
although the official statements refer to Raisman's age as a reason for his stepping down.